How this East Bay biotech pushed past the 'negativity' with a big boost to its kidney cancer drug
The questions had been circling Exelixis Inc. for the past 18 months: Was its signature drug — the one key to the company's comeback, growth and a chunk of its future plans — too late to the game of pairing up with a cancer immunotherapy to treat kidney cancer? Was the market too competitive? Would the combo of Cabometyx and Bristol-Myers Squibb Co.'s just not be enough?
The answers c ame this morning from the Alameda-based company (NASDAQ: EXEL) and Bristol-Myers Squibb (NYSE: BMY): No, Exelixis…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Ron Leuty Source Type: news
More News: Biotechnology | Cancer | Cancer & Oncology | Health Management | Immunotherapy | Kidney Cancer | Urology & Nephrology